Wogonin
| Code | Size | Price |
|---|
| TAR-T2933-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2933-20mg | 20mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2933-100mg | 100mg | £183.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Wogonin is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.
CAS:
632-85-9
Formula:
C16H12O5
Molecular Weight:
284.267
Pathway:
Stem Cells; Apoptosis; Cytoskeletal Signaling; Cell Cycle/Checkpoint; Autophagy
Purity:
0.998
SMILES:
COc1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1
Target:
Apoptosis; Wnt/beta-catenin; CDK; Autophagy
References
1. Chen LG, et al. Mol Nutr Food Res. 2008, 52(11):1349-57.
2. Polier G, et al. Cell Death Dis. 2011, 2:e182.
3. Wang W, et al. Biol Pharm Bull. 2006, 29(6):1132-7.
4. Geng X, et al. Exp Ther Med. 2015, 10(3):1066-1070.
5. Yu CS, et al. Anticancer Res. 2005, 25(1A):127-32.
6. Li HD, et al. Wogonin attenuates inflammation by activating PPAR-? in alcoholic liver disease. Int Immunopharmacol. 2017 Sep;50:95-106.
7. Zheng Z, Zhu W, Lei L, et al. Wogonin Ameliorates Renal Inflammation and Fibrosis by Inhibiting NF-?B and TGF-?1/Smad3 Signaling Pathways in Diabetic Nephropathy[J]. Drug Design, Development and Therapy. 2020, 14: 4135-4148.
8. Kuang Y, Chai Y, Xu L, et al. Glabrone as a specific UGT1A9 probe substrate and its application in discovering the inhibitor glycycoumarin[J]. European Journal of Pharmaceutical Sciences. 2021: 105786.